
Insmed (INSM) Stock Forecast & Price Target
Insmed (INSM) Analyst Ratings
Bulls say
Insmed is expected to continue its strong momentum with the recent launch of Brinsupri and successful clinical-stage programs for respiratory and inflammatory conditions. The company's focus on technology and potential for future growth in emerging markets, coupled with their strong financial performance and diverse portfolio, make them an attractive investment opportunity for long-term growth.
Bears say
Insmed is a biopharmaceutical company with a commercial portfolio and clinical pipeline focusing on three therapeutic areas. Although the company's two commercial products have shown growth, its clinical-stage programs have yet to demonstrate significant success. The company's pre-clinical research programs show promise, but are still in early stages and may not yield successful treatments in the future. Additionally, the company faces industry-wide risks such as regulatory challenges and competition. Despite these challenges, the company has potential for long-term revenue growth with the launch of their new drug Brinsupri and a strong pipeline, which our analyst believes will drive the stock price above our $212 price target in the near term.
This aggregate rating is based on analysts' research of Insmed and is not a guaranteed prediction by Public.com or investment advice.
Insmed (INSM) Analyst Forecast & Price Prediction
Start investing in Insmed (INSM)
Order type
Buy in
Order amount
Est. shares
0 shares